CyDex Pharmaceuticals announced the presentation of Phase 2 clinical trial results of its Captisol-Enabled budesonide/azelastine nasal spray (CDX-313) for seasonal allergic rhinitis (SAR).

NEW YORK (Reuters Health) - The corticosteroid drug budesonide, given as a nasal spray for 6 weeks, benefits children with mild sleep apnea, a study shows. Obstructive sleep apnea occurs when soft ...